ViaCyte
is a California-based regenerative medicine company that develops and commercializes cell replacement therapies for the treatment of diabetes... Read moreViaCyte
is a California-based regenerative medicine company that develops and commercializes cell replacement therapies for the treatment of diabetes... Read more
News
Jan 09, 2024
PharmaLive
ViaCyte: Vertex's Viacyte backs out of CRISPR diabetes deal
Mar 13, 2023
PharmaLive
ViaCyte: CRISPR/ViaCyte and Genprex vie for first diabetes gene therapy
Jul 13, 2022
Medthority
ViaCyte: Vertex Pharma acquires Viacyte to complement internal work on VX-880.
Jul 13, 2022
Global Legal Chronicle
ViaCyte: Vertex's $320 Million Acquisition of ViaCyte
Jul 12, 2022
BioPharma-Reporter
ViaCyte: Vertex to acquire ViaCyte, targeting type 1 diabetes
Jul 11, 2022
BioSpace
ViaCyte: Vertex Buys ViaCyte in Synergistic Deal Aimed at Curing Type 1 Diabetes
Jul 11, 2022
BioPharma Dive
ViaCyte: Vertex acquires another maker of potentially curative diabetes treatments
Apr 20, 2022
FirstWord Pharma
ViaCyte: ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference
Apr 20, 2022
Markets Insider
ViaCyte: ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference
Feb 03, 2022
Clinical Trials Arena
ViaCyte: CRISPR, ViaCyte dose first subject in Phase I diabetes trial
ViaCyte Competitors
1
2
3
4
5
6
7
8
9
10